title: Efficacy of latanoprost in management of chronic angle closure glaucoma.
abstract: BACKGROUND
  chronic angle closure glaucoma is often managed surgically.
  
  
  OBJECTIVE
  to study the effect of Latanoprost 0.005% on intraocular pressure in subjects diagnosed as having chronic angle closure glaucoma.
  
  
  METHODS
  forty patients participated in the study. Baseline examination included visual acuity, refraction, slit-lamp examination, intraocular pressure, anterior and posterior segment examination, gonioscopy and perimetry. Patients were treated with Latanoprost 0.005% once daily at bedtime. IOP was recorded at baseline, 2weeks, 4 weeks, 8 weeks and 12 weeks after starting the treatment.
  
  
  RESULTS
  the mean age of the study sample was 56.45 years (40-70 years). There were 18 males and 22 females in the study. Mean IOP at baseline was 24.55 +/- 3.63. Mean IOP decreased to 17.27 +/- 3.19 at 2 weeks, 15.27 +/- 3.07 at 4 weeks, 14.60-3.06 at 8 weeks and 14.47 +/- 2.66 at 12 weeks. There was a statistically significant reduction in mean IOP (41.03%) at 12 weeks as compared to those of the baseline IOP (p=0.000). There was no significant difference in IOP reduction in eyes with different degrees of angle closure by peripheral anterior synechiae.
  
  
  CONCLUSIONS
  latanoprost, a prostaglandin analogue, is effective in reducing IOP in chronic angle closure glaucoma patients and its efficacy is not affected by the degree of angle closure by peripheral anterior synechiae.
authors.affiliation: Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, Delhi.
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: A
authors.initials: A
authors.lastname: Malik
authors.forename: M
authors.initials: M
authors.lastname: Singh
authors.forename: S
authors.initials: S
authors.lastname: Sood
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy* / Q000503:physiopathology; D006068:Gonioscopy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost